Stay updated on Pralsetinib vs Standard of Care in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pralsetinib vs Standard of Care in NSCLC Clinical Trial page.

Latest updates to the Pralsetinib vs Standard of Care in NSCLC Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has undergone significant updates, including the addition of new drug information and identifiers related to RET fusion-positive non-small cell lung cancer, while removing detailed descriptions of a previous study involving pralsetinib.SummaryDifference21%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 6, 2025. However, there are no significant changes in core content, pricing, or availability.SummaryDifference0.4%
- Check37 days agoChange DetectedThe page has been updated to reflect a new version (v2.14.3) and a new last update date of March 25, 2025, replacing the previous version (v2.14.2) and date of February 6, 2025.SummaryDifference0.3%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe webpage has added several new healthcare locations in Italy, including specific hospitals and their addresses, while removing some previously listed locations and dates. Additionally, there is a notice regarding heavy traffic affecting NLM-NCBI services.SummaryDifference7%
Stay in the know with updates to Pralsetinib vs Standard of Care in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pralsetinib vs Standard of Care in NSCLC Clinical Trial page.